Registre observationnel de l’efficacité et de la tolérance de la capsa?cine 8 % (Qutenza?) dans les douleurs neuropathiques périphériques localisées pharmacorésistantes

详细信息    查看全文

• 作者：V. Beauvieux (1)
  M. -L. Navez (1)
  B. Manissol (1)
  C. Miallon (1)
  B. Pandraux (1)
  C. Créac’h (1) (2)
  
• 关键词：Douleur neuropathique ; Qutenza? ; Capsa?cine ; TRPV1 ; Neuropathic pain ; Qutenza? ; Capsaicin ; TRPV1
• 刊名：Douleur et Analg篓娄sie
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：27
• 期：2
• 页码：110-117
• 全文大小：
• 参考文献：1. Anand P, Bley K (2011) Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 107:490-02 CrossRef
  2. Attal N (2012) Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials. Contin Minneap Minn 18:161-5
  3. Backonja MM, Malan TP, Vanhove GF, et al (2010) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 11:600-
  4. Backonja M, Wallace MS, Blonsky ER, et al (2008) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 7:1106-2
  5. Bouhassira D, Attal N, Fermanian J, et al (2004) Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108:248-7
  6. Brown S, Simpson DM, Moyle G, et al (2013) NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. Aids Res Ther 10:5
  7. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-8
  8. England J, Wagner T, Kern KU, et al (2011) The capsaicin 8% patch for peripheral neuropathic pain. Br J Nurs 20:926-1
  9. European Commission Approves New Pre-treatment Options for QUTENZA(TM) (8% Capsaicin Patch) in Peripheral Neuropathic Pain. 2013 Mar 14; Available from: http://www.presseportal.de/pm/61801/2433374/european-commission-approves-new-pretreatment-options-for-qutenza-tm-8-capsaicin-patch-in
  10. Gustorff B (2012) Treatment of peripheral neuropathic pain with the capsaicin 8% patch: Is Quantitative Sensory Testing a useful tool to predict response to treatment? International congress IASP
  11. Hoper J, Helfert S, Heskam ML, et al (2013) High concentration capsaicin for treatment of peripheral neuropathic pain: Effect on somatosensory symptoms and identification of treatment responders. Curr Med Res Opin [in press]
  12. Irving GA, Backonja MM, Dunteman E, et al (2011) A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 12:99-09
  13. Irving GA, Backonja M, Rauck R, et al (2012) NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain 28:101-
  14. Kennedy WR, Vanhove GF, Lu SP, et al (2010) A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 11:579-7
  15. Maihofner C, Heskamp ML (2013) Prospective, noninterventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin 29:673-3 CrossRef
  16. Martini CH, Yassen A, Krebs-Brown A, et al (2013) A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. Eur J Pain 17:1491-01
  17. Peppin JF, Majors K, Webster LR, et al (2011) Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res 4:385-2
  18. Ragé M, Van Acker N, Facer P, et al (2010) The time course of CO2 laser-evoked responses and of skin nerve fibre markers after topical capsaicin in human volunteers. Clin Neurophysiol 121:1256-6
  19. Simpson DM, Brown S, Tobias J (2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70:2305-3 CrossRef
  20. Simpson DM, Gazda S, Brown S, et al (2010) Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage 39:1053-4
  21. Treede RD, Wagner T, Kern KU, et al (2013) Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Curr Med Res Opin 29:527-8
  22. Webster LR, Malan TP, Tuchman MM, et al (2010) A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 11:972-2
  23. Webster LR, Tark M, Rauck R, et al (2010) Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol 10:92
  
• 作者单位：V. Beauvieux (1)
  M. -L. Navez (1)
  B. Manissol (1)
  C. Miallon (1)
  B. Pandraux (1)
  C. Créac’h (1) (2)
  
  1. Centre d’évaluation et de traitement de la douleur du CHU de Saint-étienne, F-42055, Saint-étienne cedex 2, France
  2. Université Jean-Monnet, F-42023, Saint-étienne, France
  
• ISSN：1951-6398

文摘

Localized neuropathic pain may benefit from treatment with capsaicin 8% after failure of first-line therapy. The objective of the study was to evaluate in a population of drug-resistant patients, treated in a pain center for 16 months, the efficiency of Qutenza?, its tolerability and to identify predictors of favorable outcome. Of the 61 patients analyzed, the 30% reponder rate at two months was 39%. Cutaneous signs observed were always transient. The only negative predictive factor we observed was a preexisting severe cold allodynia.